Latest news with #diagnosticimaging
Globe and Mail
6 days ago
- Business
- Globe and Mail
Alfa Cytology Announces Holistic Approach to RDC Development Services Supported by In Vivo Studies in Radiopharmaceuticals
"Illustration of TAT" Alfa Cytology has announced RDC development services supported by In Vivo studies in radiopharmaceuticals. Alfa Cytology, a leading-edge biotech company engaged in cancer research, has released its services on robust RDC (Radionuclide Drug Conjugate) development technical support for radiopharmaceuticals. The services are specifically designed to transform the radiopharmaceutical industry, enhancing quality and precision for disease diagnosis and therapy. The oncology and diagnostic imaging fields are rapidly expanding, with an increasing need for transformative approaches to medical research and treatment. As current methods in disease diagnosis and treatment often lack the specificity, sensitivity, and customization demanded by the cutting edge of diagnostic medicine and theranostics, Alfa Cytology has developed the platform to meet the individualized needs of its clients. This takes a highly individualized approach, accounting for the specific biochemical and kinetic characteristics of the large variety of radiotracers and therapeutics in use. Alfa Cytology's expert services can be leveraged for the custom synthesis, optimization, and quality control of radiopharmaceuticals, to a standard of safety and efficacy unequaled by other service providers. An essential component is in vivo studies in radiopharmaceuticals. These studies, which give critical insights into the in vivo interactions and pharmacodynamics of radiopharmaceuticals, form the backbone of a rigorous approach to therapeutic radiopharmaceutical development. The research is supported by an extensive imaging and analytical infrastructure, enabling researchers to better understand the biodistribution, safety, pharmacokinetics, and overall therapeutic potential of next-generation radiopharmaceutical agents. The in vivo research option is a critical tool in efforts to develop more targeted and individualized radiopharmaceutical therapeutics and diagnostics. Alfa Cytology offers a wide range of technical support options and expert services for research teams, including custom synthesis of radiotracers, radionuclide production, labeling methodologies, and advanced analytical support to maximize radiochemical purity, as well as radioanalytical support and method development. Alfa Cytology continues to expand its service offerings and is continuously updating its highly experienced technical teams to meet the increasingly complex demands of the research community and to continue to be a resource for innovation and development in diagnostic imaging and cancer therapy. Alfa Cytology provides a fully integrated infrastructure to leverage RDC services and take advantage of cutting-edge in vivo research, connecting the laboratory to the real world. About Alfa Cytology Alfa Cytology, headquartered in New York, is a CRO company, offering state of the art solutions in radiopharmaceutical R&D. Alfa Cytology's team of industry veterans have assembled a set of broad integrated skills in molecular imaging, radiochemistry, and regulatory sciences, which allow them to provide next-generation services across the broad range of research needs within the community. For more information on the newest tools and solutions in radiopharmaceuticals, visit our service pages to learn how Alfa Cytology is redefining the future of cancer research and nuclear medicine.
Yahoo
30-06-2025
- Health
- Yahoo
Ontario to invest in community surgical centres
Canada's Ontario Government has announced an investment of C$155m ($113.47m) over two years to establish 57 new community surgical and diagnostic centres across the province. As part of Your Health: A Plan for Connected and Convenient Care, this initiative is expected to enhance access to publicly funded procedures for 1.2 million people. It will accelerate the delivery of MRI and CT scans, as well as gastrointestinal (GI) endoscopy services. Ontario premier Doug Ford said: 'It's all part of our plan to protect and improve our health-care services, all while ensuring people always receive the care they need with their OHIP card.' Starting this summer, 35 newly licensed centres will begin offering MRI and CT scan services, following a call for applications. This expansion is set to connect up to 828,000 more individuals to essential diagnostic imaging, surpassing the province's initial target by more than fourfold. The new centres will play a crucial role in lessening wait times and ensuring that patients receive scans within the recommended time. For GI endoscopy services, 22 additional licensed centres will be introduced, aiming to perform up to 420,000 procedures over two years. This marks a threefold increase over the original goal set by the province, and guarantees timely access to GI endoscopy procedures for all patients within Ontario. The announcement regarding funding was made at the Schroeder Ambulatory Centre in Richmond Hill, which has been allocated C$14m to provide MRI and CT scans, along with GI endoscopy services, to more than 115,000 patients over two years. The names of the other recipient centres will be disclosed in the following weeks. New centres are mandated to present detailed staffing strategies to maintain stability at public hospitals, report into the province's wait times information system, and engage in regional central intakes where available. In addition, all community surgical and diagnostic centres will fall under the remit of Accreditation Canada's recently introduced programme for quality assurance. This initiative enforces the same stringent standards as public hospitals. "Ontario to invest in community surgical centres" was originally created and published by Hospital Management, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
CBC
06-06-2025
- Health
- CBC
Nova Scotia recoups $3.7M in health-transfer clawbacks from Ottawa
Ottawa has paid Nova Scotia several million dollars in health transfers that were previously withheld because of people paying out of pocket for private MRIs and ultrasounds. According to the federal government, no one in Canada should pay for medically necessary diagnostic imaging services, and it's been clawing back money from Nova Scotia and other provinces for allowing it to happen. However, Nova Scotia and Ottawa have come to an agreement that recently resulted in a reimbursement of $3.79 million — the total amount clawed back over the past three years. The payment was finalized in March. "It's been a long time coming," said Katherine Fierlbeck, a professor of political science at Dalhousie University who studies health policy. She noted many other provinces have already made arrangements to reduce or eliminate privately funded medical imaging to have their health transfers reimbursed. Fierlbeck said she has a long list of questions about the details of the agreement, some of which she's hoping will be answered in Health Canada's annual report on transfer payments. The report is typically tabled in Parliament each March, but the House wasn't sitting from the start of January to the end of May — the result of a prorogation and then the federal election. The report has yet to be tabled since the new session began last week. Health Canada released the reimbursement numbers to CBC News on request, along with a brief explanation. Contract with private clinic A spokesperson for Health Canada said the key reason for the reimbursement is "efforts taken by Nova Scotia to eliminate patient charges at the private clinic." The private clinic they refer to is Healthview, which offers MRIs and ultrasounds. Nova Scotia Health (NSH) signed a contract with the Halifax imaging clinic last May to send some patients there at the public expense. A spokesperson for NSH said 2,278 MRIs and 585 ultrasounds were publicly funded at Healthview in the first year of the five-year, $7.6-million agreement. Patients who NSH sends to Healthview are triaged in the same way as patients who go to public clinics. Privately funded imaging continues But the contract with Healthview does not entirely eliminate cases of patients paying for medically necessary imaging. Healthview still accepts patients who want to pay to jump the queue, and at least two other private clinics in Halifax do the same. Wosler Diagnostics opened last summer, offering ultrasound only, and Why Wait Imaging opened earlier this year, offering ultrasounds and MRIs. NSH confirmed it does not have contracts with either of these clinics. Fierlbeck said this is hard to reconcile with the fact the province received a full reimbursement of health transfer clawbacks. WATCH | Why Nova Scotia was losing out on health transfer payments: Why N.S. is losing out on health transfers as private medical imaging grows 5 months ago Duration 2:18 With long waits for ultrasounds and MRIs, some Nova Scotians are paying to get care sooner at private clinics. But Ottawa says those services should be publicly funded and it's punishing Nova Scotia for allowing patients to pay. Taryn Grant has the story. "If it's only partial coverage, I would have thought that the ministry would say 'OK, partial coverage, we'll give you partial reimbursement,'" Fierlbeck said. She said covering some services at private clinics — but not all — makes for a "thinly veiled two-tier system." The Nova Scotia Department of Health and Wellness would not make anyone available for an interview. Health authority working on imaging backlogs The underlying issue that's pushing many Nova Scotians to seek private medical imaging is a backlog in the public health-care system, with some people waiting months or years for MRIs and ultrasounds. Dr. Tim Mailman said the problem is complex and has been years in the making, but Nova Scotia Health is "laser-focused" on improvements. Mailman, senior medical director of the diagnostics and therapeutic services network, said the main bottleneck is staffing; there's a shortage of imaging technologists. "Let's use MRI as an example," he said in an interview earlier this year. "If we were able to run our current MRIs across the province [for] extended hours, we have enough MRIs to meet the demand." Mailman said there's a "complex workforce strategy" in the works to address that issue. Additionally, Mailman said the health authority is working on a central intake system to streamline booking. He said he expects it will reduce duplication and no-shows, and ultimately shorten wait times. The health authority is expecting the system to come online this summer. Mailman said the health authority is also working on training and support for clinicians to make sure they're sending patients for the most appropriate type of imaging. "As a provider myself, I can tell you it's not always easy … I still call my phone-a-friend radiologist to say, 'With this specific situation, should I be asking for a CT? Should I be asking for an MRI?' "It's not policing the resources, it's working with providers," he said.
Yahoo
11-05-2025
- Business
- Yahoo
Earnings To Watch: RadNet (RDNT) Reports Q1 Results Tomorrow
Diagnostic imaging company RadNet (NASDAQ:RDNT) will be announcing earnings results tomorrow morning. Here's what you need to know. RadNet beat analysts' revenue expectations by 4.2% last quarter, reporting revenues of $477.1 million, up 13.5% year on year. It was a strong quarter for the company, with an impressive beat of analysts' same-store sales and EPS estimates. Is RadNet a buy or sell going into earnings? Read our full analysis here, it's free. This quarter, analysts are expecting RadNet's revenue to grow 2.6% year on year to $443 million, slowing from the 10.5% increase it recorded in the same quarter last year. Adjusted loss is expected to come in at -$0.13 per share. Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. RadNet has a history of exceeding Wall Street's expectations, beating revenue estimates every single time over the past two years by 3.5% on average. Looking at RadNet's peers in the testing & diagnostics services segment, some have already reported their Q1 results, giving us a hint as to what we can expect. Guardant Health delivered year-on-year revenue growth of 20.8%, beating analysts' expectations by 6.9%, and NeoGenomics reported revenues up 7.5%, falling short of estimates by 1.7%. Guardant Health traded up 3.7% following the results while NeoGenomics was down 35.9%. Read our full analysis of Guardant Health's results here and NeoGenomics's results here. Investors in the testing & diagnostics services segment have had steady hands going into earnings, with share prices up 1.5% on average over the last month. RadNet is up 4.4% during the same time and is heading into earnings with an average analyst price target of $71.67 (compared to the current share price of $55.73). Here at StockStory, we certainly understand the potential of thematic investing. Diverse winners from Microsoft (MSFT) to Alphabet (GOOG), Coca-Cola (KO) to Monster Beverage (MNST) could all have been identified as promising growth stories with a megatrend driving the growth. So, in that spirit, we've identified a relatively under-the-radar profitable growth stock benefiting from the rise of AI, available to you FREE via this link. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
